{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "MANE",
  "name": "Veradermics, Incorporated",
  "url": "https://frontierpicks.com/dossiers/MANE/",
  "json_url": "https://frontierpicks.com/dossiers/MANE.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Extended-release oral minoxidil story: Study '302' showed +30.3/+33.0 hairs/cm² vs +7.3 placebo at Month 6 (2026-04-27, p<0.0001), and the confirmatory Study '304' topline guided to 2H26 is the binary. The 2026-09-04 close of $98.51 sits under the $100.00 April 29 follow-on print with RSI(14) at 33.2 — a well-known story whose flow has thinned while the readout has no confirmed date.",
  "invalidation_trigger": "A weekly close below $85 (loses the $100.00 April 29, 2026 follow-on placement zone by a wide margin), or 2026-12-31 arriving with the guided 2H26 Study '304' topline unreported.",
  "catalyst_date": "2026-09-09",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech",
    "fintech-consumer-credit"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage: no approved product and no product revenue; every valuation input is a probability-weighted VDPHL01 outcome.",
    "Listed 2026-02-04 at a $17.00 IPO price — under eight months of trading history, so long-horizon technical structure does not exist yet.",
    "VDPHL01 competes against off-label generic oral minoxidil already dispensed cheaply through telehealth channels.",
    "Company guides cash into 2030 from $819.9M held on 2026-06-30; any raise before the '304' readout would contradict that guidance."
  ],
  "body_markdown": "## Current Thesis\n\nVeradermics is a clinical-stage dermatology company whose value sits almost entirely in one asset: VDPHL01, an extended-release oral minoxidil for pattern hair loss. On 2026-04-27 the company reported Part A topline from Study '302' — non-vellus target area hair count at Month 6 rose +30.3 hairs/cm² on 8.5 mg once-daily and +33.0 hairs/cm² twice-daily against +7.3 for placebo, both p<0.0001, with separation already visible at Month 2, the earliest timepoint measured. The narrative leg being bought is replication: a confirmatory Phase 3, Study '304' (536 men, two dose regimens, 52 weeks), completed enrollment on 2026-02-09 and topline is guided to 2H26, alongside 12-month data from '302' in the same window. Nothing about the story resolves before those prints land, and the tape has been drifting toward the April placement price while it waits — the 2026-09-04 close was $98.51 with RSI(14) at 33.2.\n\n## Bull Case\n\n- **Effect size is large and the statistics are not marginal.** Study '302' Part A (2026-04-27): +30.3 (QD) and +33.0 (BID) hairs/cm² versus +7.3 placebo at Month 6, p<0.0001 on both arms.\n- **Patient-reported outcomes moved with the hair counts.** On the AAIRS scale at Month 6, 62.9% of BID patients reported themselves improved or much improved versus 13.4% on placebo (p<0.0001) — a readout that matters for a cash-pay category where the buyer is the patient.\n- **The safety question specific to oral minoxidil was addressed in the same release.** Adverse-event rates were comparable to placebo, discontinuations ran lower than placebo, and the company reported no treatment-related serious adverse events and no adverse events of cardiac origin.\n- **Readout timing is no longer enrollment-dependent.** Enrollment in the confirmatory Study '304' completed 2026-02-09; the female Phase 2/3 Study '306' has completed enrollment at 556 participants with topline guided to 1H27.\n- **The second population produced a positive Phase 2 in July 2026.** Study '207' in female pattern hair loss reported rapid onset and consistent response, per the Q2 2026 earnings release of 2026-08-11.\n- **Funding is not the constraint through the data.** Cash, equivalents and marketable securities stood at $819.9M on 2026-06-30, which the company states funds operations into 2030 through multiple Phase 3 readouts and a potential VDPHL01 launch. Q2 2026 EPS of $(0.58) beat the $(0.65) consensus (Benzinga, 2026-08-11).\n\n## Bear Case\n\n- The 2026-09-04 close of $98.51 is under the price at which that block was distributed.\n- **The sell-side has already published the win.** StockAnalysis.com shows 7 covering analysts with a \"Strong Buy\" average rating and an average 12-month price target of $163.50 as of early September 2026. Unanimous coverage before the confirmatory readout leaves the upside case dependent on estimates rising rather than on coverage initiating.\n- **Operating cost is stepping up ahead of any approval.** Q2 2026 G&A was $10.9M against $1.7M in Q2 2025; R&D $18.6M against $14.3M; net loss $23.5M against $15.6M (8-K exhibit, 2026-08-11).\n- **A confirmatory trial can miss.** Study '304' is a different, larger, 52-week protocol than the six-month '302' primary. Consistency across '302' Part A does not make replication a formality, and the guidance is a half-year window (\"2H26\"), not a date.\n- **Oral minoxidil is already prescribed off-label as a cheap generic** and distributed through telehealth channels. VDPHL01 has to convert a formulation-and-label advantage into pricing power in a category where the incumbent alternative costs very little.\n- **There is no group to lean on.** No sector cluster currently carries this name; the move is single-stock and event-driven, so a soft biotech tape offers no offsetting bid.\n\n## Setup & Price Structure\n\nThe last completed daily close was $98.51 on 2026-09-04, with the shares up 9.1% over three months and RSI(14) at 33.2. That combination describes a stalled advance rather than a break: the post-topline range has been building beneath the $100.00 April 29 offering print, and momentum has bled off while the fundamental record has not changed since 2026-08-11.\n\nThe listing is seven months old — so there is no multi-year structure to reference and no monthly base to appeal to. The two levels with real information content are both public prints: the $17.00 IPO and the $100.00 follow-on. Holders from February sit on very large embedded gains, which is the mechanical source of supply on any disappointment; the April buyers are the marginal cohort, and $100.00 is the line that shows whether they are whole.\n\nOn positioning, the narrative is maturing — the hair-loss story has been fully absorbed into sell-side coverage since the 2026-04-27 topline, the equity has been distributed twice inside six months, and the bid has not widened since the follow-on closed on 2026-05-01, with the decisive '304' print still outstanding. An oversold RSI reading into an unresolved binary is a description of thinning flow, not of accumulation. The three September conference appearances are visibility events, not data events.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-08** — Wells Fargo 21st Annual Healthcare Conference, Boston; investor meetings only, no webcast (announced 2026-09-03).\n- **2026-09-09, 3:00 p.m. ET** — Citi 2026 Biopharma Back to School Conference presentation, New York; webcast, replay ~30 days.\n- **2026-09-10, 3:20 p.m. ET** — 2026 Cantor Global Healthcare Conference presentation, New York; webcast. First public forum since the 2026-08-11 Q2 release at which '304' timing could be tightened.\n- **2H26, date not scheduled** — Study '304' confirmatory Phase 3 topline in male pattern hair loss, and 12-month data from Study '302'. Both are guided to the second half of 2026; neither has a company-confirmed date, so the window can close on 2026-12-31 without a print.\n- **~2026-11-10 (est.)** — Q3 2026 results; the Q2 release landed 2026-08-11, no date confirmed.\n\n## What Would Change Our Mind\n\nThe cleanest break is scientific: Study '304' reporting without a statistically significant hair-count separation from placebo on the primary endpoint, or a safety signal — particularly a cardiac one — that '302' did not surface. Second is the calendar: 2026-12-31 arriving with the \"2H26\" guidance unmet and no topline, which turns a four-month binary into an open-ended wait while G&A runs above $10M a quarter. Third is corporate: any new equity raised before the '304' readout, which would contradict the stated runway into 2030 and put fresh paper into a market already trading under the last placement price.\n\nOn the tape, a weekly close below $85 would say the April $100.00 cohort has stopped defending the placement and that the readout is being discounted as a risk rather than as an event. Conversely, a weekly close back above $100.00 — the April print — is the observable that would show the bid rebuilding ahead of data rather than after it.\n\n## Correlation Notes\n\nNo theme cluster currently carries this name, so this is a single-name, event-driven setup rather than a group trade — a claim resting on a sector move here would be unsupported. The read-throughs that do exist: broad clinical-stage biotech risk appetite (the XBI complex), which sets the discount rate on a pre-revenue balance sheet holding $819.9M as of 2026-06-30; and the consumer cash-pay hair-loss channel, where telehealth dispensers of compounded and generic oral minoxidil are both the competitive backdrop and the eventual commercial partner set. Inference, not measurement: a soft biotech tape can push the shares through the $100.00 placement line without any company-specific news, because the only company-specific news scheduled between now and year-end is a readout with no date on it.",
  "first_seen": "2026-09-03",
  "last_analyzed": "2026-09-06T08:07:54+00:00",
  "last_synthesized": "2026-09-05",
  "last_update_source": "research_universe",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}